Patients with ROS1-positive non-small cell lung cancer often have limited options once resistance develops to earlier targeted therapies. Jideytro (zidesamtinib) addresses this need as a next-generation ROS1-selective kinase inhibitor approved for adults whose disease has progressed after prior ROS1 inhibitor treatment.
Designed with high selectivity and strong penetration into the central nervous system, Jideytro aims to overcome resistance mutations while also addressing brain metastases, a common challenge in advanced NSCLC.
Its approval strengthens the precision oncology landscape and is expected to make it a key comparator in future lung cancer studies. Monitoring market uptake, exclusivity, and supply availability will be important for both clinical development and first-to-file planning.
